share_log

We Think That There Are Some Issues For Beijing Wandong Medical TechnologyLtd (SHSE:600055) Beyond Its Promising Earnings

We Think That There Are Some Issues For Beijing Wandong Medical TechnologyLtd (SHSE:600055) Beyond Its Promising Earnings

我們認爲,除了可觀的收益外,北京萬東醫療科技股份有限公司(SHSE: 600055)還有一些問題
Simply Wall St ·  03/30 07:06

The stock price didn't jump after Beijing Wandong Medical Technology Co.,Ltd. (SHSE:600055) posted decent earnings last week. Our analysis showed that there are some concerning factors in the earnings that investors may be cautious of.

繼北京萬東醫療科技股份有限公司之後,股價沒有上漲。, Ltd.(上海證券交易所股票代碼:600055)上週公佈了不錯的收益。我們的分析表明,收益中存在一些令人擔憂的因素,投資者可能會謹慎行事。

earnings-and-revenue-history
SHSE:600055 Earnings and Revenue History March 29th 2024
SHSE: 600055 收益和收入歷史記錄 2024 年 3 月 29 日

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

For anyone who wants to understand Beijing Wandong Medical TechnologyLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥47m worth of unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. Beijing Wandong Medical TechnologyLtd had a rather significant contribution from unusual items relative to its profit to December 2023. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

對於任何想了解北京萬東醫療科技有限公司在法定數字之外的利潤的人來說,值得注意的是,在過去的十二個月中,從價值4700萬元人民幣的不尋常物品中獲得了法定利潤。雖然我們希望看到利潤增加,但當不尋常的物品做出重大貢獻時,我們往往會更加謹慎一些。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。這正如你所預料的那樣,因爲這些增強被描述爲 “不尋常”。截至2023年12月,北京萬東醫療科技有限公司的不尋常項目對其利潤做出了相當大的貢獻。在其他條件相同的情況下,這可能會使法定利潤成爲衡量潛在盈利能力的不良指導。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Beijing Wandong Medical TechnologyLtd.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對北京萬東醫療科技有限公司的資產負債表分析。

Our Take On Beijing Wandong Medical TechnologyLtd's Profit Performance

我們對北京萬東醫療科技有限公司盈利表現的看法

As previously mentioned, Beijing Wandong Medical TechnologyLtd's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. As a result, we think it may well be the case that Beijing Wandong Medical TechnologyLtd's underlying earnings power is lower than its statutory profit. The good news is that its earnings per share increased slightly in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. In terms of investment risks, we've identified 2 warning signs with Beijing Wandong Medical TechnologyLtd, and understanding these should be part of your investment process.

如前所述,北京萬東醫療科技有限公司不會無限期地從不尋常項目中獲得巨額提振,因此其法定收益可能無法指導其潛在盈利能力。因此,我們認爲北京萬東醫療科技有限公司的基礎盈利能力很可能低於其法定利潤。好消息是,其每股收益在去年略有增長。歸根結底,如果你想正確地了解公司,必須考慮的不僅僅是上述因素。請記住,在分析股票時,值得注意所涉及的風險。在投資風險方面,我們已經向北京萬東醫療科技有限公司確定了兩個警告信號,了解這些信號應該是您投資過程的一部分。

Today we've zoomed in on a single data point to better understand the nature of Beijing Wandong Medical TechnologyLtd's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我們放大了單一數據點,以更好地了解北京萬東醫療科技有限公司利潤的性質。但是,還有很多其他方法可以讓你對公司的看法。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論